Background: Hepatocellular carcinoma (HCC) is one of the most common malignant tumors worldwide as well as in Egypt where it constitutes a significant public health problem. HCC is the third most common cause of death from cancer and chronic infection with HBV and HCV are the most important precursors for HCC development. Objective: To study the epidemiologic, clinical and pathological features of advanced HCC in clinical oncology and Nuclear medicine department, Suez Canal University hospital. Method: This is a retrospective study done to analyse the clinical, demographic and pathological data of advanced HCC patients that attended clinical oncology and Nuclear Medicine Department, Suez Canal University Hospital in the period between January 2013 and December 2016. Results: Results revealed that mean age of the patients was 60.2 ± 7.69, 71.74% male and 28.26% Female, 91.3% were HCV positive while 6.5% were HBV positive. Liver cirrhosis was in 89.13% of patients. Majority of the patients (78.2%) were child Pugh Score B and 21.7% were child Pugh Score C. 67.39% of patients had diabetes. Portal vein thrombosis was present in 50% of cases. Alpha fetoprotein was elevated >400 in 56.52% of cases. Thirty four patients received treatment in the form of chemotherapy while 12 patients did not receive treatment. There is a highly significant increase in survival time P < 0.001 in treated group compared to untreated group. Median survival time (in months) was five months in the treated group versus one month in the untreated group. Conclusion: HCC is one of the increasing major health problems in both developing and developed countries. The most important risk factor is cirrhosis which is mainly due to HCV infection. Thus, much effort should be put into the field of prevention and treatment of viral hepatitis infections and chronic liver disease. Screening programs should be done to get rid of the problem, and most importantly, there must be an acceptable and effective therapy for HCC.
Introduction
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer (Poustchi, 2010) [1] . Worldwide, liver cancer is the fifth and seventh most common cancer in men and women, respectively. Regions of high incidence include Eastern and South-Eastern Asia, Middle and Western Africa (Ferlay, et al., 2014) [2] . HCC is the third most common cause of death from cancer.
HCC high fatality is reflected in high mortality (0.93) to incidence ratio (Ferlay, et al., 2014) [2] .
In Egypt, liver cancer is the fourth most common cancer and is the second cause of cancer mortality in both sexes (Ferlay, et al., 2014) [2] .
Risk factors of HCC are many and include viral hepatitis C (HCV) and B (HBV), cirrhosis, alcohol, aflatoxins, male sex and smoking (Ahmed and Rabinovitz, 2005) [3] . Chronic infection with HBV and HCV are the most important precursors for HCC development, together accounting for over 80% of liver cancer cases worldwide (Bosch, et al., 1999) [4] .
In Egypt, HCV is the main risk factor for HCC where 71% of HCC cases are positive for anti-HCV antibodies (Rahman, et al., 2001 ) [5] .
A considerable number of patients are diagnosed at advanced stage with poor prognosis and a median overall survival (OS) of about 6 months. Sorafenib is the only approved front-line molecular-targeted treatment with slight survival benefits. It improves survival with median OS rate of 6.5 -10.7 months (Llovet, et al., 2008 ) [6] .
Prognosis of advanced HCC is poor with median OS less than 6 months. This is even less in low and middle income countries, where resources and access to therapy are limited (Llovet, et al., 1999) [7] .
The aim of this study was to analyze the epidemiologic and clinical characteristics of advanced HCC cases at Clinical Oncology and Nuclear Medicine Department, Suez Canal University in the period from January 2013 to December 2016.
Patient and Methods
This is a retrospective study in which all cases of advanced HCC attended clini- Abdominal pain was the first presenting symptom in 73.91% of cases (Table 3) .
Majority of patients (47.83%) presented with stage III a ( Table 4) . Most of patients were metastatic (54.35%) while 45.65% did not have metastasis (Table 5 ).
Portal vein thrombosis was present in 50% of cases (Table 6 ). Alpha Fetoprotein Chi-square test: a-P < 0.001.
was elevated >400 in 56.52% of cases (Table 7) . Hepatic encephalopathy was the commonest cause of death which was in 43.48% of patients (Table 8) . (Table 10 and Figure 1 ). Chi-square test: P < 0.001. Chi-square test: a-P < 0.001. 
Discussion
Hepatocellular carcinoma is a major health problem in Egypt and many patients present with advanced disease beyond curative surgery and effective local and The advantage of the current study is that it included patients received treatment and patients that did not receive treatment due to refusal, unavailability or [8] who found in his study on HCC that majority of patients 79% were males and 21% were females. This may be in part explained by differences in exposure to risk factors. Also, Kuman R et al. 2008 [9] in India, mentioned that the incidence of HCC in males is higher than females.
As regards hepatitis, 91.3% of our patients were HCV+ve, while 6.5% were
HBV+ve. This is in agreement with other studies as Gomaa Our results showed that the most common extrahepatic metastases of hepatocellular carcinoma were abdominal lymph nodes 30.4% followed by bone 13.04% a and lung 10.87%. This is in agreement with the studies done by Natsuizaka MI et al., 2005 [14] who found that the lung, abdominal lymph nodes and bone are the most common sites of extrahepatic metastatic HCC but with different arrangement as they mentioned that the most common site was the lung, abdominal lymph nodes and bone.
As regards portal vein thrombosis, it was present in 50% of cases. This is in 
Conclusions
HCC is one of the increasing major health problems in both developing and developed countries. HCC (>80%) majorly presents with advanced or unresectable diseases. Most HCC patients have underlying cirrhosis with impaired hepatic function.
Owing to the aggressive biology of the disease and the limited treatment options for HCC patients as well as the limited resources or access to treatment for most of Egyptian patients like sorafenib or liver transplant, we found that HCC is a fatal disease and constitutes a major national problem. Thus, we have to find other effective treatment modalities or try to stress the importance of screening programs which can enable diagnosis at an early stage with the opportunity for treatment with curative intent. The most valuable solution is to put more effort into a prevention program, through prevention of infection by viral hepatitis or treating it at earlier stages before causing cirrhosis which is the main risk factor for HCC in Egypt.
Therefore, improving screening, early detection and access to therapy may improve outcome of HCC.
